IP Library Granted Patent US 9,896,691
Granted Patent B2
US 9,896,691 · App. 14/268,796 · Granted Feb 20, 2018

Compositions and methods for lipid production

Inventors: John Blazeck (Austin, TX); Andrew Hill (Austin, TX); Leqian Liu (Austin, TX); Hal Alper (Austin, TX)
Assignee: Board of Regents, The University of Texas System
C12N15/815C07K14/39C12N1/16C12N9/0006C12N9/0008C12N9/0042C12N9/0077C12N9/1007C12N9/78C12N9/88C12N9/93C12N15/01C12N15/52C12P7/64C12P7/6409C12P7/6463C12R1/645
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,896,691
App. No.
14/268,796
Granted
Feb 20, 2018
Kind
B2
Abstract

Described herein, inter alia, are compositions, oleagnious organisms, and methods useful for producing lipids, lipid precursors, and/or oleochemicals.

Claims (14)

1. A method of producing a lipid, lipid precursor, or oleochemical comprising:

a) culturing a genetically modified yeast cell in a growth medium; and

b) isolating said lipid, lipid precursor, or oleochemical,

wherein the dry weight of said genetically modified yeast cell comprises greater than 60% wt/wt lipids, lipid precursors, and oleochemicals; and

wherein said genetically modified yeast cell comprises (i) a recombinant acyl-CoA:diacylglycerol acyltransferase 1 (DGA1) gene and a UGA2 succinate semialdehyde dehydrogenase (UGA2) gene comprising a mutation, wherein said mutation results in a loss of function of succinate semialdehyde dehydrogenase of 20% or more compared to succinate semialdehyde dehydrogenase encoded by UGA2 without the mutation; or (ii) a recombinant acyl-CoA:diacylglycerol acyltransferase 2 (DGA2) gene and a UGA2 succinate semialdehyde dehydrogenase (UGA2) gene comprising a mutation, wherein said mutation results in a loss of function of succinate semialdehyde dehydrogenase of 20% or more compared to succinate semialdehyde dehydrogenase encoded by UGA2 without the mutation.

2. The method of claim 1 , wherein said growth medium comprises a majority carbon source selected from the group consisting of glucose, glycerol, xylose, fructose, mannose, ribose, sucrose, and lignocellulosic biomass.

3. The method of claim 1 , wherein said growth medium comprises lignocellulosic biomass as the majority carbon source.

4. The method of claim 1 , wherein said growth medium comprises cobalt, iron, magnesium, potassium, zinc, nickel, molybdenum, manganese, copper, or boron.

5. The method of claim 1 , wherein said growth medium comprises 5.77×10 −5 M to 1.73×10 −4 M cobalt, 0.001 M to 0.003 M magnesium, 4.52×10 −5 M to 1.35×10 −4 M potassium, 4.05×10 −5 M to 1.22×10 −4 zinc, 3.55×10 −5 M to 1.06×10 −4 manganese, 9.07×10 −5 M to 2.91×10 −4 boron, 3.76×10 −5 M to 1.10×10 −5 molybdenum, 2.28×10 −5 M to 6.84×10 −5 nickel, 3.60×10 −5 M to 1.08×10 −4 iron, or 4.70×10 −5 M to 1.41×10 −4 copper.

6. The method of claim 1 , wherein said genetically modified yeast cell comprises a recombinant Lipid synthesis regulator (MGA2) gene, a genetically modified Lipid synthesis regulator (MGA2) gene, a recombinant Leucine Biosynthesis gene (LEU2), a genetically modified multifunctional enzyme (MFEI) gene, a genetically modified PEX10 Transcription Factor (PEX10) gene or a recombinant AMP Deaminase (AMPD) gene.

7. The method of claim 1 , wherein said genetically modified yeast cell comprises a genetically modified multifunctional enzyme (MFE1) gene and a genetically modified PEX10 Transcription Factor (PEX10) gene.

8. The method of claim 1 , wherein said genetically modified yeast cell comprises a recombinant Leucine Biosynthesis gene (LEU2), a genetically modified multifunctional enzyme (MFEI) gene and a genetically modified PEX10 Transcription Factor (PEX10) gene.

9. The method of claim 1 , wherein said genetically modified yeast cell comprises a genetically modified multifunctional enzyme (MFEI) gene, a genetically modified PEX10 Transcription Factor (PEX10) gene and a recombinant AMP Deaminase (AMPD) gene.

10. The method of claim 1 , wherein said genetically modified yeast cell comprises a recombinant Leucine Biosynthesis gene (LEU2), a genetically modified multifunctional enzyme (MFEI) gene, a genetically modified PEX10 Transcription Factor (PEX10) gene and a recombinant AMP Deaminase (AMPD)) gene.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 19, 2023
From: BLAZECK, JOHN; HILL, ANDREW; LIU, LEQIAN; ALPER, HAL
To: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
Reel/Frame 065911/0958 →
EXECUTIVE ORDER 9424, CONFIRMATORY LICENSE Recorded May 26, 2016
From: TEXAS, UNIVERSITY OF
To: NAVY, SECRETARY OF THE UNITED STATES OF AMERICA
Reel/Frame 038823/0635 →
CONFIRMATORY LICENSE Recorded Jul 13, 2015
From: TEXAS, UNIVERSITY OF
To: NAVY, SECRETARY OF THE UNITED STATES OF AMERICA
Reel/Frame 036106/0558 →
Continuity (2)
Provisional Application 61819476 · May 3, 2013
Related Publication 20140329287A1 · Nov 6, 2014